123 related articles for article (PubMed ID: 37243480)
1. Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients.
Griguolo G; Aldegheri V; Bottosso M; Pittaro A; Caumo F; Guarascio MC; Pouderoux S; Busato F; Miglietta F; Jacot W; Dieci MV; Darlix A; Guarneri V
Int J Cancer; 2023 Sep; 153(6):1217-1226. PubMed ID: 37243480
[TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal metastases: a RANO proposal for response criteria.
Chamberlain M; Junck L; Brandsma D; Soffietti R; Rudà R; Raizer J; Boogerd W; Taillibert S; Groves MD; Le Rhun E; Walker J; van den Bent M; Wen PY; Jaeckle KA
Neuro Oncol; 2017 Apr; 19(4):484-492. PubMed ID: 28039364
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
4. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal.
Le Rhun E; Devos P; Boulanger T; Smits M; Brandsma D; Rudà R; Furtner J; Hempel JM; Postma TJ; Roth P; Snijders TJ; Winkler F; Winklhofer S; Castellano A; Hattingen E; Capellades J; Gorlia T; Van den Bent M; Wen PY; Bendszus M; Weller M;
Neuro Oncol; 2019 May; 21(5):648-658. PubMed ID: 30715514
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
6. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
Le Rhun E; Devos P; Winklhofer S; Lmalem H; Brandsma D; Kumthekar P; Castellano A; Compter A; Dhermain F; Franceschi E; Forsyth P; Furtner J; Galldiks N; Gállego Pérez-Larraya J; Gempt J; Hattingen E; Hempel JM; Lukacova S; Minniti G; O'Brien B; Postma TJ; Roth P; Rudà R; Schaefer N; Schmidt NO; Snijders TJ; Thust S; van den Bent M; van der Hoorn A; Vogin G; Smits M; Tonn JC; Jaeckle KA; Preusser M; Glantz M; Wen PY; Bendszus M; Weller M
Neuro Oncol; 2022 Oct; 24(10):1726-1735. PubMed ID: 35157772
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
[TBL] [Abstract][Full Text] [Related]
9. Earliest radiological progression in glioblastoma by multidisciplinary consensus review.
Eijgelaar RS; Bruynzeel AME; Lagerwaard FJ; Müller DMJ; Teunissen FR; Barkhof F; van Herk M; De Witt Hamer PC; Witte MG
J Neurooncol; 2018 Sep; 139(3):591-598. PubMed ID: 29777418
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR.
Seong M; Park S; Kim ST; Park SG; Kim YK; Kim HJ; Ahn MJ
J Neurooncol; 2020 Sep; 149(2):367-372. PubMed ID: 32897466
[TBL] [Abstract][Full Text] [Related]
11. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases.
Jaeckle KA; Dixon JG; Anderson SK; Moreno-Aspitia A; Colon-Otero G; Hebenstreit K; Patel TA; Reddy SL; Perez EA
Cancer Med; 2020 Nov; 9(21):7935-7942. PubMed ID: 32885617
[TBL] [Abstract][Full Text] [Related]
12. A Comparative Retrospective Study of Immunotherapy RANO
Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
Front Oncol; 2021; 11():679331. PubMed ID: 34249718
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
14. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
15. Effect of MRI-based semiautomatic size-assessment in cerebral metastases on the RANO-BM classification.
Bauknecht HC; Klingebiel R; Hein P; Wolf C; Bornemann L; Siebert E; Bohner G
Clin Neuroradiol; 2020 Jun; 30(2):263-270. PubMed ID: 31197388
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of patients with breast cancer-related leptomeningeal metastases.
Le Rhun E; Taillibert S; Zairi F; Pannier D; Boulanger T; Andre C; Cazin JL; Dubois F; Bonneterre J; Chamberlain MC
Anticancer Res; 2013 May; 33(5):2057-63. PubMed ID: 23645756
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status.
Xu H; Chen H; Kong J; Zhang Y; Liu S; Yang G; Yang L; Wang Y
Ann Transl Med; 2021 Jun; 9(11):937. PubMed ID: 34350252
[TBL] [Abstract][Full Text] [Related]
18. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
19. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
20. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
